Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Examine the Potential Effect of Lansoprazole on the Pharmacokinetics of Bosutinib When Administered Concomitantly to Healthy Subjects.

Next Previous
Trial Profile

A Study to Examine the Potential Effect of Lansoprazole on the Pharmacokinetics of Bosutinib When Administered Concomitantly to Healthy Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bosutinib (Primary) ; Lansoprazole (Primary)
  • Indications Breast cancer; Chronic myeloid leukaemia; Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastro-oesophageal reflux; Heartburn; Helicobacter infections; NSAID-induced ulcer; Peptic ulcer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours; Zollinger-Ellison syndrome
  • Focus Pharmacokinetics
  • Sponsors Wyeth

Most Recent Events

  • 18 Apr 2011 Planned End Date changed from 1 Sep 2009 to 2 Sep 2009, according to ClinicalTrials.gov record.
  • 03 Sep 2010 Additional location [USA] identified as reported by ClinicalTrials.gov.
  • 21 Jun 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top